AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

Address: da Vinci Building, Melbourn Science Park, Melbourn
Postcode: SG8 6EE
Country: United Kingdom
Membership type:Enhanced Founder

Our skills focus on the discovery, development and commercialisation of medicines for the treatment of some of the world’s greatest healthcare challenges.  Our commitment to making a meaningful difference in healthcare is founded on the pursuit of scientific excellence that addresses unmet patient need. Science is at the heart of AstraZeneca’s future strategy and success – and our aspiration is to achieve scientific leadership. 

In March 2013, we announced our UK global R&D centre and corporate headquarters will be based at the Cambridge Biomedical Campus.  The new, purpose-built site will be home to around 2000 highly-skilled staff, as part of our plan to create strategic global R&D centres in Britain, the United States and Sweden.  This will bring together our small molecule and biologics activity, creating opportunities to capitalise on the promise of small and large molecule combinations, improving pipeline productivity and establishing AstraZeneca as a global leader in biopharmaceutical innovation.

The Biomedical Campus will also become our largest centre for oncology research, as well as hosting our work on cardiovascular and metabolic diseases, respiratory, inflammatory, autoimmune and nervous system conditions. Projects here will also include medicinal chemistry and high-throughput screening, and the facility will accommodate a number of pre-clinical research capabilities.

AstraZeneca has a long-standing presence in the UK and we're proud to be developing the next generation of medicines in Cambridge. 

AstraZeneca in Cambridge

AstraZeneca in Cambridge

In March 2013, we announced plans to establish a new Global R&D Centre and Corporate Headquarters in Cambridge on the Cambridge Biomedical Campus, the future home to approximately 2,000 employees. In February 2015, Cambridge City Council granted planning permission for our new site.

AstraZeneca in the UK

A global pharmaceutical company with a major UK presence. Through innovation and collaboration we can achieve better health for all.

Structure of a human ATM dimer

High tech collaboration reveals the dynamic structure of ATM

An advanced cryo-electron microscope allows AstraZeneca and Laboratory for Molecular Biology (LMB) scientists in Cambridge to uncover ground-breaking insights into a prime therapeutic target in cancer.

23 May 2017Read in full

AstraZeneca and Pieris Pharmaceuticals collaborate on treatments for respiratory diseases

AstraZeneca has announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

4 May 2017Read in full

AstraZeneca's bladder cancer drug gets FDA approval

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab).

1 May 2017Read in full

Tagrisso receives full approval in the EU

AstraZeneca today announced that the European Commission (EC) has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).

26 April 2017Read in full

topping out ceremony with a tree

AstraZeneca's key milestone: ‘topping out’ of new global R&D centre and HQ in Cambridge UK

Latest milestone since AstraZeneca moved its global HQ and strategic science hub to Cambridge, UK, where the company already has 2,000 employees

25 April 2017Read in full

Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer

AstraZeneca’s breast cancer treatment, Lynparza (olaparib), provided a statistically-significant improvement in progression-free survival compared to chemotherapy in the first positive randomised trial to evaluate the efficacy and safety of a PARP inhibitor beyond ovarian cancer.

17 February 2017Read in full

AstraZeneca and Lilly to develop treatment for Alzheimer’s disease

AstraZeneca and Eli Lilly and Company have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which is currently in Phase I trials as a potential disease-modifying treatment for Alzheimer’s disease (AD). This agreement builds on the existing collaboration related to AZD3293, a BACE inhibitor in two pivotal Phase III trials.

4 January 2017Read in full

Repositive and AstraZeneca announce members of PDX consortium

Repositive, a software company developing novel tools to improve discovery and access to human genomic research data, and AstraZeneca have announced the inaugural members of the PDX Consortium, which was set up to develop a collaborative, pre-competitive resource, to provide streamlined discovery and access to molecular data from Patient Derived Xenografts (PDXs) for use within oncology research.

7 December 2016Read in full

AstraZeneca takes latest scientific advances in oncology to major US And European congresses

AstraZeneca and its global biologics research and development arm, MedImmune, will continue the oncology momentum built during 2016 with a strong end-of-year presence at three major congresses.

29 November 2016Read in full

Woman providing education and awareness

AstraZeneca climbs eight positions in Access to Medicine Index

The highest climber in the 2016 Index, AstraZeneca is now ranked seventh overall in providing access to medicine.

15 November 2016Read in full

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. ...
  12. 17

IMED Early Phase Drug Discovery Graduate Programme - UK

Are you a 2017 science graduate with a top-class Bachelor’s degree or Master’s – or will you be gaining such a degree in 2018? ...

Location: Cambridge
Salary: Unspecified
More Info

IT Graduate Associate - UK

At AstraZeneca we believe in the potential of our people and you’ll develop beyond what you thought possible. We make the most o...

Location: Cambridge
Salary: Unspecified
More Info

Real World Evidence Senior Data Scientist/Data Scientist

At AstraZeneca we work together across global boundaries to make an impact and find answers to challenges. We do this with the u...

Location: Cambridge
Salary: Unspecified
More Info

Administration Assistant

At AstraZeneca we win through science, it’s at the heart of our every success. That science is only possible when we all work to...

Location: Cambridge
Salary: Unspecified
More Info

Director - Finance Master Data

At AstraZeneca every one of our employees makes a difference to patient lives every day. In Finance you may not feel you're at t...

Salary: Unspecified
More Info

Senior Counsel, Product & Portfolio Legal

At AstraZeneca, we’re not afraid to do things differently. We’re building a new kind of organisation to reset expectations of wh...

Location: Cambridge
Salary: Unspecified
More Info

Senior Programmer - Neuroscience, Immunology & Respiratory

At AstraZeneca every one of our employeesmakes a difference to patient lives everyday. Each and every one of us believes that sc...

Location: Cambridge
Salary: Unspecified
More Info